Drinking Bone Broth But Joints Still Ache? Your Genes May Be Why.

COL1A1 encodes collagen type I, the primary structural protein in bone matrix and skin. Think of collagen as the steel reinforcement in concrete. The collagen molecules need to be cross-linked together to create strength and resilience. COL1A1 controls how efficiently those cross-links form.

The Sp1 site variant in COL1A1 (rs1800012), carried by roughly 15-20% of the population, reduces the efficiency of collagen cross-linking. This means the collagen molecules in your bones are mechanically weaker, even if you have plenty of them. Your bone mineral density may look normal on a scan, but the structural integrity is compromised. You’re essentially building bone with inferior materials.

This is why you might drink bone broth, increase your collagen intake, and still feel joint instability or notice that your fracture risk hasn’t improved. Your body is getting the raw collagen, but it’s not being assembled into resilient bone matrix. You feel this as weak joints, joint hypermobility, or unexpected fractures from minor injuries.

IL6 is a cytokine that signals your immune system to activate inflammation. In the context of joints, elevated IL-6 tells your body to activate osteoclasts, the cells that break down bone. When IL-6 signaling is overactive, your body resorbs bone faster than it rebuilds it, regardless of how much collagen you consume.

The -174G>C variant in IL6 (rs1800795), present in roughly 40% of the population, is associated with higher baseline IL-6 production. People with this variant often have chronically elevated IL-6 levels, which keeps osteoclast activity high and bone remodeling tilted toward breakdown rather than formation. The RANKL signaling pathway, which activates bone-eating cells, is constantly being amplified by your elevated IL-6.

This shows up as joint inflammation that doesn’t respond to rest, persistent joint pain despite good collagen intake, or progressive bone loss visible on serial scans even though you’re doing everything right. Your immune system is actively dismantling your bones faster than you can rebuild them.

TNF-alpha is one of the most powerful inflammatory cytokines in your body. It activates immune cells, triggers inflammation cascades, and directly tells osteoclasts to break down bone. TNF-alpha is particularly important in rheumatoid arthritis and chronic inflammatory joint conditions. When TNF signaling is overactive, inflammation becomes self-perpetuating and bone loss accelerates.

The -308G>A variant in TNF (rs1800629), carried by roughly 30% of the population, is associated with higher TNF-alpha production. People with this variant have a genetic predisposition toward higher-baseline inflammation, which means their immune system is more aggressive in attacking joint tissue and signaling bone breakdown. This is a major risk factor for inflammatory arthritis and rapid bone loss.

You experience this as persistent joint swelling that doesn’t improve with rest, morning joint stiffness that takes hours to resolve, joint pain that worsens with stress or illness, or unexpectedly rapid progression of arthritis despite anti-inflammatory efforts. Your immune system is treating your joints as a threat.

VDR is the receptor that vitamin D binds to in order to tell your body to absorb calcium from your intestines and deposit it into your bones. Without functional VDR, you cannot absorb calcium efficiently, no matter how much bone broth you drink. VDR variants are among the most significant genetic drivers of osteoporosis risk and low bone mineral density.

VDR has multiple common variants (BsmI, FokI, TaqI), and roughly 30-50% of the population carries a functional variant that reduces VDR expression or sensitivity. People with these variants absorb calcium less efficiently, maintain lower circulating calcium levels, and have reduced bone mineral density even on adequate vitamin D and calcium intake. Your bones are literally using less of the minerals you’re providing.

You notice this as persistent low bone density despite adequate calcium intake, stress fractures or unexpected fractures from minor injuries, slow healing after bone injuries, or dental problems like receding gums despite good oral hygiene. Your body isn’t mineralizing bone the way it should.

COL11A1 encodes collagen type XI, a minor collagen component of cartilage that’s essential for cartilage extracellular matrix integrity. While collagen type I is the structural framework of bone, collagen type XI is woven into cartilage to give it shape, elasticity, and resistance to compression. COL11A1 variants affect how well cartilage resists wear and how quickly it degenerates.

Variants in COL11A1, present in roughly 20-30% of the population, reduce cartilage matrix integrity and are strongly associated with early osteoarthritis, particularly in the knee and hip. These variants also increase the likelihood of joint hypermobility, where joints are unstable and move beyond their normal range. People with COL11A1 variants have cartilage that degenerates faster and is more susceptible to damage from normal activities.

This shows up as joint clicks and cracks even at rest, a sense of instability in knees or hips, cartilage damage visible on imaging despite minimal injury history, or early osteoarthritis in your 40s or 50s when your parents didn’t develop it until much later. Your cartilage is structurally compromised.

GDF5 is a growth factor that shapes how your joints develop and how they respond to injury or inflammatory signals. GDF5 controls joint size, cartilage thickness, and the body’s response to joint degeneration. It’s one of the key signals that determines whether your joints are robust or vulnerable to arthritis.

The rs143384 variant in GDF5, carried by roughly 40% of the population, reduces GDF5 expression and is strongly associated with osteoarthritis risk, particularly in the knee and hip joints. People with this variant have joints that are genetically predisposed to degeneration. Even if you do everything right with collagen intake, anti-inflammatory management, and exercise, your joints are starting from a position of reduced resilience.

You experience this as joints that feel less stable than those of your peers, early cartilage wear visible on imaging, joint pain that seems disproportionate to your activity level, or osteoarthritis developing years earlier than expected. Your joints were shaped differently in development and are more vulnerable to stress.